Now livetag icon
AI created more apps than ever, but 75% won't make it. Find out how to win. Download the reportbanner icon
Replimune

May 2026

Replimune Market Share Analysis for May 2026

. The Company discovers and develops oncolytic immunotherapy for the treatment of patients with cancer diseases. Replimune Group serves customers in the United States. CURRENT PRICE. REPL:US9.50USD.
Year Founded2015
Employees201 - 500
Annual Revenue$5M - $10M
replimune.com
Replimune
Replimune (including company regionals)
  • replimune.com
    replimune.com
See more website traffic and engagement information

Replimune Revenue up to May 2026 is 5M - 10M

revenue generated by Replimune top domains

Replimune top domains revenue over 3 years

Revenue for Replimune top domains


Total visits to Replimune's top domains

Understand Replimune market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in Replimune's top domains

Analyze Replimune engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on Replimune's top domains

See how Replimune keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.



Top technologies used by Replimune

These are the website technologies, by industry, used by Replimune top domains

Payment & Currencies (10)

Cart Functionality

Cart Functionality

eCommerce (6)

OpenCart

OpenCart

Widget (4)

Twemoji

Twemoji

Advertising (3)

DoubleClick

DoubleClick

More Technologies

9

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from Replimune

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsReplimune Group attended event 2026 American Society of Clinical Oncology annual meeting on May 30th '26.WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting.
NewsReplimune Group had issues with violations of the securities laws on May 17th '26.LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of the securities laws.
NewsReplimune Group decreases headcount by 224.Replimune cuts 224 jobs in Massachusetts after second FDA rejection of RP1.

See all Replimune signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.